Affibody AB appoints Dr. Ulf Boberg as Chief Executive Officer
Affibody AB announced that Dr. Ulf Boberg has been appointed Chief Executive Officer as from June 1, 2006.
Dr. Ulf Boberg, who joined Affibody in January 2006 as Senior Vice President Development, replaces Dr. Carl-Johan Dalsgaard who as been acting Chief Executive Officer of Affibody since December 2005. Dr. Dalsgaard is a partner of Affibody's largest shareholder HealthCap and will remain a non-executive board member of Affibody. Dr. Boberg holds a PhD in medical science, an MBA from Uppsala University and has 18 years experience from the pharmaceutical and biotechnology industry. Most recently, Dr. Boberg was CEO of Global Genomics AB. Before that, he held the senior roles of vice president and head of the Development Division at Astra Pain Control, leading a team of 170 people, and vice president and R&D site general manager at AstraZeneca. In 2000, Dr. Boberg left AstraZeneca to become investment manager at LinkMed AB. Earlier in his career, he held positions including Head of Medical Research at Gambro, CEO of PMC Clinical Research AB and CEO of Alfta Rehab Center.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.